<DOC>
	<DOCNO>NCT02939846</DOCNO>
	<brief_summary>Present clinical study conduct China evaluate pharmacokinetics single repeat oral dos trametinib , safety profile clinical activity Chinese subject solid tumor . Approximately 10 evaluable subject enrol study , Subjects receive trametinib 2 mg daily ( QD ) . Study treatment continue disease progression , death unacceptable toxicity . The study complete subject discontinue study treatment last enrolled subject least 16 week follow-up , whichever occurs first .</brief_summary>
	<brief_title>Pharmacokinetics Single Repeat Oral Doses Trametinib Chinese Subjects With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<criteria>Provided sign write informed consent Males females ≥18 year age ( time consent obtain ) . Histologically cytologically confirm diagnosis locally advance metastatic solid tumour , melanoma subject eligible BRAF V600 mutation confirm tumour tissue qualify clinical laboratory . The disease responsive standard therapy , approve curative therapy . Performance Status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Adequate baseline organ function define : Absolute neutrophil count ( ANC ) : &gt; =1,200 /microliter ( uL ) ; Hemoglobin : &gt; =9 gram ( g ) /deciliter ( dL ) ; Platelets : &gt; =75,000 /uL ; Prothrombin time/ International normalization ratio activate partial thromboplastin time : &lt; =1.5 x Upper Limit Normal ( ULN ) ; Total bilirubin : &lt; =1.5 x ULN ; Aspartate aminotransferase Alanine aminotransferase : &lt; =2.5 x ULN ; Calculated creatinine clearance ( Calculate creatinine clearance use standard CockcroftGault formula ) : &gt; =50 milliliter ( mL ) / minute ( min ) 24hour urine creatinine clearance &gt; =50 mL/min ; Left ventricular Ejection fraction ( LVEF ) : &gt; /= 50 % LVEF case establish Lower limit normal ( LLN ) give institution . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Subjects prior Whipple procedure ( pancreaticoduodenectomy ) eligible ( meet criterion ) . Men female partner childbearing potential must either prior vasectomy agree use effective contraception time first dose trametinib 16 week last dose trametinib . Women childbearing potential must negative serum pregnancy test within 7 day first dose study treatment agree use effective contraception 14 day prior enrolment , throughout treatment period 4 month last dose study treatment . Pregnant Lactating female . History another malignancy . Exception : Subjects diseasefree 5 year , subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . Use investigational drug within 28 day five halflives , whichever longer precede first dose trametinib . Previous treatment MEK inhibitor . History sensitivity study medication , component thereof history drug allergy , opinion investigator subinvestigator , contraindicate participation . History interstitial lung disease pneumonitis . Current use prohibit medication describe Section 10.2 . •Colonystimulating factor like filgrastim prohibit treatment prophylactic management . Any major surgery , radiotherapy , immunotherapy within 21 day initiation trametinib . Chemotherapy regimens delay toxicity within 21 day initiation trametinib ( 42 day prior nitrosourea mitomycin C ) . Chemotherapy regimens give continuously weekly basis limit potential delayed toxicity within two week initiation trametinib . Note : Use bisphosphonates consider supportive care use permit . History current evidence / risk retinal vein occlusion ( RVO ) central serous retinopathy ( CSR ) : Uncontrolled glaucoma ocular hypertension , uncontrolled systemic disease hypertension , diabetes mellitus , history hyperviscosity hypercoagulability syndrome ) . Visible retinal pathology assess ophthalmic exam consider risk factor RVO CSR : Evidence new optic disc cup Evidence new visual field defect automate perimetry Intraocular pressure &gt; 21mm Hg measure tonography Symptomatic uncontrolled leptomeningeal brain metastasis spinal cord compression . Subjects previously treat condition stable central nervous system ( CNS ) disease asymptomatic corticosteroid , stable dose corticosteroid least 1 month prior study Day 1 eligible . Subjects eligible receive enzyme induce antiepileptic drug ( EIAEDs ) . QTc B ≥ 480 msec . History acute coronary syndrome ( include unstable angina ) , coronary angioplasty , stenting within past 24 week . History evidence current ≥ Class II congestive heart failure define New York Heart Association . History evidence current clinically significant uncontrolled arrhythmia . • Subjects control atrial fibrillation &gt; 1 month prior study Day 1 eligible . History Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) infection . • Subjects laboratory evidence clear HBV and/or HCV permit , define HBs antigen negative HBV DNA negative ( HBV DNA result mandatory either HBc HBs antibody positive ) ; HCV antibody negative . History HIV infection . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , hepatic , renal , cardiac disease ) . Have know immediate delay hypersensitivity reaction idiosyncrasy dimethyl sulfoxide ( DMSO ) . Any serious unstable preexist medical condition ( aside malignancy exception specify ) , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent , compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Trametinib</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>